Invalidating Immunological Indifference for Prostate Cancer

Saturday, February 13, 2016
Guillermo Martinez, University of Monterrey, Monterrey, Mexico
Cytotoxic T cells have the competence to attack cancer cells and eradicate a complete tumor. However, this mechanism has showed challenging for two motives. First, T cells and other elements of the immune system ignore self-molecules and cells. Second, tumor microenvironment has immunosuppressive elements capable of producing a mechanism called immunological tolerance. CD4+ T cells generate signaling molecules and activate immune cells that deliver efficient CD8+ T cell response. CD70 is essential for dendritic cells-facilitated delay of T cell tolerance initiation. CD80 and CD86 cells are implicated in the refunctionalizing the tolerized T cell. Here, these cells (CD4+, CD8+, CD70, CD80 and CD86) were obtained from a tumor prostate tissue treated with androgen ablation and were applied in a mouse model of prostate cancer. Count cell number and purity for the particular cell population was realized by flow cytometric analysis. Preliminary results report that the activity of the CD8+T cells persisted for up to 45 days after treatment with CD4, CD70, CD80 and CD86 cells, and resulted in a significant diminution of tumor size. The stimulation of T cell infiltration and other immune cells in cancer tissues could have effects for the immunotherapeutic treatment of other hormone–related malignant tumors.